Allergan (AGN) says Darpin data does not support Phase 3 trials.

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. RARE
4. HPE
5. FIVE

6. SPY
7. VRTS
8. NTAP
9. NTSK
10. OLLI

May 1, 2013 11:08 AM EDT

Price: $193.02 --0%

Overall Analyst Rating:
SELL (= Flat)

Dividend Yield: 1.6%

UPDATE: Allergan, Inc. (NYSE: AGN) says Darpin data does not support Phase 3 trials. (halted on breaker)

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!